Oramed Pharmaceuticals Inc. (ORMP) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. Oramed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on oral delivery of therapeutic proteins, primarily oral insulin. The company is currently navigating a strategic pivot involving a joint venture (JV) with Hefei Tianhui Biotech Co., Ltd. (HTIT) to form OraTech, alongside significant financial investments in Scilex Holding Company, Alpha Tau Medical Ltd., and real estate projects.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2025 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|---|
| Revenues | $2,000 | $0 | $0 |
| Operating Loss | $(6,989) | $(2,489) | $(6,097) |
| Financial Income, Net | $12,808 | $15,366 | $19,322 |
| Net Income | $5,618 | $13,260 | $10,738 |
| Cash and Cash Equivalents (End of Period) | $15,797 | N/A | |
| Short-Term Deposits | $22,865 | N/A | |
| Total Current Assets | $99,026 | N/A | |
| Total Current Liabilities | $3,693 | N/A | |
| Working Capital Surplus | $95,333 | N/A |
Material Changes vs. Prior Period
- Revenue Recognition: The company recognized $2.0 million in revenue during the six months ended June 30, 2025, compared to zero in the prior year. This resulted from the waiver of claims by HTIT under the amended Joint Venture Agreement, allowing the recognition of previously deferred revenue from the Technology License Agreement.
- Cost of Revenue: A one-time cost of $1.987 million was recognized in the six months ended June 30, 2025, related to the repayment of grants to the Israel Innovation Authority (IIA) to facilitate the transfer of technology to the new joint venture entity, OraTech.
- Financial Income: Net financial income decreased to $12.8 million (six months 2025) from $19.3 million (six months 2024). This decline was driven by lower revaluation gains on Scilex and RoyaltyVest investments, partially offset by a significant unrealized gain of $7.4 million on the new investment in Alpha Tau Medical Ltd.
- Operating Expenses: Research and Development (R&D) expenses increased 24% year-over-year for the six-month period ($3.24M vs $2.62M) due to preparations for a new Phase 3 clinical trial (ORA-D-013-3). However, R&D expenses decreased 28% quarter-over-quarter ($1.03M vs $1.44M) due to reduced stock-based compensation and clinical trial costs.
- Liquidity: Cash and cash equivalents decreased significantly from $54.4 million at year-end 2024 to $15.8 million at June 30, 2025. This reduction was primarily due to capital deployment into Alpha Tau ($36.9M), RoyaltyVest, and real estate loans (Hapisga and Tova Chochma).
Guidance, Outlook, and Risks
- JV Status: The closing of the Joint Venture Agreement with HTIT is currently on hold due to U.S.-China trade tensions preventing HTIT from obtaining necessary regulatory approvals. Consequently, plans to initiate the Phase 3 clinical trial in the U.S. have been paused. Management is evaluating alternative partners or independent pathways.
- Scilex Transactions: The company holds significant assets related to Scilex, including Tranche A and B Notes and warrants. In July 2025 (subsequent event), Oramed entered an Option Agreement allowing Scilex to repurchase 6.5 million Subsequent Penny Warrants for $27 million. Completion of this repurchase would extend the Tranche A Note maturity to March 2026.
- Investment Strategy: The company is actively diversifying its capital allocation through real estate loans (Hapisga, Tova Chochma) and equity investments (Alpha Tau, BioXcel via RoyaltyVest) to generate income and value appreciation while core R&D is paused.
- Capital Resources: Management believes current cash resources and commitments are sufficient to maintain planned activities for at least the next 12 months.
- Risks: Key risks include the failure of the HTIT JV to close, the inability to monetize Scilex warrants due to Nasdaq listing restrictions, potential decline in value of the Alpha Tau investment if clinical trials fail, and geopolitical risks in Israel.
Investor Verification Checklist
- JV Regulatory Hurdles: Verify the status of HTIT's regulatory approvals and the likelihood of the OraTech spin-off proceeding as planned.
- Scilex Warrant Monetization: Confirm the progress of the $27 million warrant repurchase agreement and the financial health of Scilex to fulfill this obligation.
- Alpha Tau Clinical Data: Monitor upcoming clinical trial results for Alpha Tau Medical Ltd., as the value of Oramed's $36.9M investment is highly dependent on these outcomes.
- Real Estate Loan Security: Assess the collateral coverage and repayment status of the $26.9M in real estate loans (Hapisga and Tova Chochma).
- Cash Burn Rate: Track the company's cash burn rate given the pause in the Phase 3 trial and the shift toward investment income as a primary revenue driver.